10-Q · May 7, 2026
InspireMD reported Q1 2026 revenues of $3.398 million, exceeding estimates by 17.85%. This represents a 122% year-over-year growth, while EPS improved to -$0.14 from -$0.18 in the prior year. Management signals ongoing…
Earnings analysis · 10-Q
NSPR earnings analysis
Filed August 14, 2026 · Our reading of the company's report
The latest report
The supplied 10-Q text is materially negative because management disclosed substantial doubt about continuing as a going concern and the company faces a Nasdaq minimum-bid-price deficiency requiring remediation by…
Read full summary
The supplied 10-Q text is materially negative because management disclosed substantial doubt about continuing as a going concern and the company faces a Nasdaq minimum-bid-price deficiency requiring remediation by January 13, 2027. The May 2026 voluntary recall of CGuard Prime adds product, regulatory, revenue, and litigation risk. The provided extract does not include Q2 2026 income-statement, balance-sheet, segment, or cash-flow tables, so current-period financial metrics and trends cannot be independently verified.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
Disclosure controls deemed effective
Management concluded that disclosure controls and procedures were effective at the reasonable-assurance level as of June 30, 2026.
-
No material control changes
The company reported no material changes to internal control over financial reporting during the quarter ended June 30, 2026.
What to watch
-
Substantial doubt over going concern
Management concluded that substantial doubt exists regarding the company’s ability to continue as a going concern. The concern is tied to recurring losses and negative operating cash flows for the quarter ended June 30, 2026, and could limit access to new financing on reasonable terms or at all.
-
Nasdaq listing deficiency
Nasdaq notified InspireMD on July 17, 2026 that it was below the $1.00 minimum bid-price requirement. The company has until January 13, 2027—180 calendar days from the notice—to regain compliance by maintaining a closing bid price of at least $1.00 for 10 consecutive business days.
-
CGuard Prime recall
In May 2026, the company announced a voluntary U.S. recall of CGuard Prime after controlled launch testing showed that delivery-system technical success during carotid artery stenting procedures had not met performance expectations. The recall could result in inventory write-offs, refunds, lost revenue, regulatory action, litigation, and reputational damage.
Management's outlook
No quantitative revenue or EPS outlook was provided in the supplied 10-Q text; numeric outlook may be addressed in the earnings release or conference call.
Earlier filings 4
10-K · March 18, 2026
InspireMD (NSPR) is transitioning from a Europe/distributor business to a U.S. commercial stage company after FDA PMA approval of CGuard Prime on June 23, 2025 and a U.S. launch in July 2025. Clinical evidence…
10-Q · November 10, 2025
Revenue rose 39.4% year-over-year to $2,523,000 in Q3 2025 while gross margin expanded to 34.2% from 22.9%, driven by the U.S. commercial launch of CGuard Prime. However, net loss widened to $12,708,000 (up $4,818,000…
10-Q · November 12, 2024
InspireMD reported Q3 revenue of $1,810 (thousands), up from $1,556 in the prior-year quarter, but losses widened as operating expenses rose to $8,876 (thousands) and net loss was $(7,890) for the quarter. Cash +…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.